Vericel Q4 2022 Earnings Report $57.61 +0.11 (+0.19%) As of 04:00 PM Eastern Earnings HistoryForecast Vericel EPS ResultsActual EPS$0.12Consensus EPS $0.02Beat/MissBeat by +$0.10One Year Ago EPS$0.09Vericel Revenue ResultsActual Revenue$52.70 millionExpected Revenue$52.95 millionBeat/MissMissed by -$250.00 thousandYoY Revenue Growth+10.70%Vericel Announcement DetailsQuarterQ4 2022Date2/23/2023TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseVCEL Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Vericel Earnings HeadlinesVericel Corporation: Hard To Justify Current ValuationDecember 20, 2024 | seekingalpha.comVericel (VCEL) Receives a Buy from TD CowenDecember 18, 2024 | markets.businessinsider.com⭕ [URGENT] Buy Alert just triggeredThis opportunity is killer. The smart money is already buying up shares in this company keeping the AI boom alive.January 6, 2025 | Behind the Markets (Ad)BTIG Reaffirms Their Buy Rating on Vericel (VCEL)December 7, 2024 | markets.businessinsider.comHunting For Magnificent Growth Next Year? Check Out These 7 Stocks.December 3, 2024 | investors.comLeerink Partners Sticks to Its Buy Rating for Vericel (VCEL)November 28, 2024 | markets.businessinsider.comSee More Vericel Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vericel? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vericel and other key companies, straight to your email. Email Address About VericelVericel (NASDAQ:VCEL), a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.View Vericel ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
